Scalable synthesis of reduced toxicity derivative of amphotericin B

US10683318B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10683318-B2
Application numberUS-201816148255-A
CountryUS
Kind codeB2
Filing dateOct 1, 2018
Priority dateOct 17, 2014
Publication dateJun 16, 2020
Grant dateJun 16, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed is a simplified, readily scalable series of individual methods that collectively constitute a method for the synthesis of C2′epiAmB, an efficacious and reduced-toxicity derivative of amphotericin B (AmB), beginning from AmB. Also provided are various compounds corresponding to intermediates in accordance with the series of methods.

First claim

Opening claim text (preview).

We claim: 1. A compound, represented by wherein, independently for each occurrence, R 1 is C(O)OR a ; R 2 is selected from the group consisting of 2-alken-1-yl, benzyl, and (R b ) 3 Si—; R 3 is substituted or unsubstituted aryl, or C 1 -C 6 alkyl; R a is selected from the group consisting of tert-butyl, and benzyl; and R b is substituted or unsubstituted aryl, or C 1 -C 6 alkyl. 2. The compound of claim 1 , wherein R 2 is 2-alken-1-yl; and R 3 is substituted or unsubstituted aryl. 3. A compound, represented by wherein, independently for each occurrence, R 1 is C(O)OR a ; R 2 is selected from the group consisting of 2-alken-1-yl, benzyl, and (R b ) 3 Si—; R 3 is substituted or unsubstituted aryl, or C 1 -C 6 alkyl; R 4 is —C(O)R c ; R a is selected from the group consisting of 2-alken-1-yl, tert-butyl, and benzyl; R b is substituted or unsubstituted aryl, or C 1 -C 6 alkyl; and R c is substituted or unsubstituted aryl. 4. The compound of claim 3 , wherein R a is 2-alken-1-yl; R 2 is 2-alken-1-yl; R 3 is substituted or unsubstituted aryl; and R c is substituted or unsubstituted phenyl. 5. The compound of claim 3 , represented by 6. A compound, represented by wherein, independently for each occurrence, R 1 is C(O)OR a ; R 2 is selected from the group consisting of 2-alken-1-yl, benzyl, and (R b ) 3 Si—; R 3 is substituted or unsubstituted aryl, or C 1 -C 6 alkyl; R 4 is —C(O)R c ; R 5 is (R b ) 3 Si—; R a is selected from the group consisting of 2-alken-1-yl, tert-butyl, and benzyl; R b is substituted or unsubstituted aryl, or C 1 -C 6 alkyl; and R c is substituted or unsubstituted aryl. 7. The compound of claim 6 , wherein R a is 2-alken-1-yl; R 2 is 2-alken-1-yl; R 3 is substituted or unsubstituted aryl; R c is substituted or unsubstituted phenyl; and R b is C 1 -C 6 alkyl. 8. The compound of claim 6 , represented by 9. A compound, represented by wherein, independently for each occurrence, R 1 is C(O)OR a ; R 2 is selected from the group consisting of 2-alken-1-yl, benzyl, and (R b ) 3 Si—; R 3 is substituted or unsubstituted aryl, or C 1 -C 6 alkyl; R 5 is (R b ) 3 Si—; R a is selected from the group consisting of 2-alken-1-yl, tert-butyl, and benzyl; and R b is substituted or unsubstituted aryl, or C 1 -C 6 alkyl. 10. The compound of claim 9 , wherein R a is 2-alken-1-yl; R 2 is 2-alken-1-yl; R 3 is substituted or unsubstituted aryl; and R b is C 1 -C 6 alkyl. 11. The compound of claim 9 , represented by 12. A method of making 2′epiAmB, comprising the step of: wherein, independently for each occurrence, R 1 is C(O)OR a ; R 2 is selected from the group consisting of 2-alken-1-yl, benzyl, and (R b ) 3 Si—; R 3 is substituted or unsubstituted aryl, or C 1 -C 6 alkyl; R 4 is —C(O)R c ; R 5 is (R b ) 3 Si—; R a is selected from the group consisting of 2-alken-1-yl, tert-butyl, and benzyl; R b is substituted or unsubstituted aryl, or C 1 -C 6 alkyl; R c is substituted or unsubstituted aryl; M is an alkali metal cation or alkaline earth metal cation; and solvent 6 is a polar aprotic solvent, a polar protic solvent, or a mixture thereof. 13. The method of claim 12 , wherein M is an alkali metal cation. 14. The method of claim 12 , wherein solvent 6 is a mixture of a polar aprotic solvent and a polar protic solvent. 15. The method of claim 12 , wherein R 4 is p-(tert-butyl)benzoyl. 16. The method of claim 12 , wherein M is K. 17. The method of claim 12 , wherein solvent 6 is a mixture of tetrahydrofuran (THF) and MeOH. 18. The method of claim 12 , wherein R 4 is p-(tert-butyl)benzoyl; M is K; and solvent 6 is a mixture of tetrahydrofuran (THF) and MeOH.

Assignees

Inventors

Classifications

  • Processes for the preparation of sugar derivatives · CPC title

  • C07H17/08Primary

    Hetero rings containing eight or more ring members, e.g. erythromycins · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10683318B2 cover?
Disclosed is a simplified, readily scalable series of individual methods that collectively constitute a method for the synthesis of C2′epiAmB, an efficacious and reduced-toxicity derivative of amphotericin B (AmB), beginning from AmB. Also provided are various compounds corresponding to intermediates in accordance with the series of methods.
Who is the assignee on this patent?
Univ Illinois
What technology area does this patent fall under?
Primary CPC classification C07H17/08. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).